Maintenance of platelet inhibition during antiplatelet therapy

A method for maintaining or reducing platelet activity in a patient comprising:

• administering to the patient a therapeutically effective amount of cangrelor prior to the patient undergoing an invasive procedure wherein oral administration of platelet inhibition therapy is contra-indicated.

A method of maintaining or reducing platelet activity in a patient in need thereof comprising:

• administering to a patient in need thereof an effective amount of cangrelor prior to undergoing a invasive procedure wherein the measured P2Y12 reaction unit (PRU) is maintained at or below about 240 during administration of cangrelor.

A method of maintaining or reducing platelet activity comprising:

• administering to a patient in need thereof an effective amount of cangrelor wherein the patient was previously treated with a thienopyridine prior to undergoing an invasive procedure wherein at least about 60% of the platelet activity is inhibited.

A method of maintaining or reducing platelet activity prior to undergoing an invasive procedure, comprising:

• administering a therapeutically effective amount of cangrelor to a patient in need thereof wherein the P2Y12 reaction unit (PRU) level is at or below 240, ceasing administration of cangrelor wherein the PRU levels is similar to pre cangrelor administration levels, prior to said patient undergoing an invasive procedure.

The method of treating or preventing thrombosis comprising:

• administering a therapeutically effective amount of cangrelor to a patient in need thereof where said patient was previously treated with a long-acting irreversible platelet inhibitor, wherein the risk of bleeding is not increased.

A method of reducing platelet activity in a patient in need thereof comprising:

• administering during the perioperative period to a patient in need of an invasive procedure a therapeutically effective amount of cangrelor wherein the measured P2Y12 reaction unit (PRU) is below 240.